Is your approach to managing immune related adverse events altered at all in light of COVID-19?  

First of all, I wish to thank @Benjamin P. Levy from Johns Hopkins/Sibley for his advice addressing this critical topic.We are all witnessing a rapidly evolving crisis that none of us have been prepared for and it is the right thing to quickly consider as best as we can how the COVID-19 pandemi...

I appreciate the excellent response and community coming together to share knowledge. At the risk of overloading with resources and content, there is a podcast by the Uromigos group (group of Urologic Oncologists) that discuss this topic at the link below and a written section compiled by Dr. Doug J...